School of Medicine
Showing 1-20 of 21 Results
-
Cailin Collins, MD PhD
Postdoc Res Affiliate, Medicine - Med/Hematology
Postdoc Res Affiliate, Stem Cell Bio Regenerative Med InstituteBioReceived her undergraduate degree from Williams College, after which she spent one year conducting research at the NIH National Cancer Institute. She then attended medical school at the University of Michigan, where she also completed a PhD in Molecular and Cellular Pathology as part of the Medical Scientist Training Program. She completed residency at UCSF prior to starting Hematology and Oncology fellowship training at Stanford. Her prior research has focused on the transcription factor biology and deregulated signaling pathways in hematologic malignancies. She is currently a postdoctoral fellow in Dr. Ravi Majeti's lab studying clonal hematopoiesis and preleukemic stem cells.
-
Michitaka Nakano
Basic Life Research Scientist, Medicine - Med/Hematology
BioI am a MD/PhD postdoctoral fellow and medical oncologist with a long-standing interest in translational cancer research. My long-term goal is to be a lab-based physician-scientist and independent academic researcher, translating basic cancer research, and mentoring next-generation scientists. My thesis work in Japan focused on cancer stem cell equilibrium by uniquely applying organoid culture as a method to elucidate cancer stem cell dynamics, which was awarded in Japanese Cancer Association. Along with the development of the field represented by success in T cell checkpoint, my interest gradually shifted to immune oncology while I examined numerous numbers of cancer patients as a medical oncology fellow. My postdoctoral fellowship at Calvin Kuo Lab in Stanford (2019-present) focuses on tumor immune microenvironment. Kuo lab developed a unique 3D air-liquid interface (ALI) organoid system that cultures tumors while preserving their endogenous infiltrating immune cells (T,B ,NK, Myeloid cells). My postdoctoral work will prove the significance of organoids as a translational tool to discover tumor-immune interaction by novel checkpoint inhibitors for immune cells, which can be broadly applicable to basic cancer biology, precision medicine, therapeutics validation and biomarker discovery.
